Nanoresistance
Management of Resistance to Tyrosine Kinase Inhibitors with Advanced Nanosystems

Educational Material

Short Course:
Nanotheranostics: all-in-one personalized medicine

Delivered during the 2013 International Conference on Nanotheranostics (ICoN 2013)

This short course provided an overview of the major concepts behind the newly created field of nanotheranostics. Nanotheranostic agents have a number of significant advantages over current approaches: (i) Nanotheranostic agents can be customized to the disease and personalized to the patient. (ii) Active targeting and localization allows for better treatment with much less intense side effects compared to current regimens. (iii) The integration of therapy and monitoring provides real-time information on whether or not the specific treatment regimen is working for the specific patient. Given these attributes, it is not surprising that the field of nanotheranostics is considered the future of treatment of highly inhomogeneous and variable diseases such as cancer and chronic inflammatory disorders. The course included the following subjects:

• Introduction Going to the lower limits: nanotechnology and nanomedicine Theranostics: all-in-one personalized medicine (Andreani Odysseos, EFB, EPOS-Iasis R&D Ltd, Cyprus)
• Theranostic Nanoparticles (Rena Bizios, University of Texas at San Antonio, USA)
• Clinical applicability of Optical Imaging (Costas Pitris, University of Cyprus, Cyprus)
• Nanotheranostics at the clinical fore Image-guided therapy: paving the way of nanotheranostic agents to the clinic Monitoring therapy by imaging (Andreani Odysseos, EFB, EPOS-Iasis R&D Ltd, Cyprus)
• Image-guided quantification of drug delivery and development (Costas Pitris, University of Cyprus, Cyprus)
• Discussion of Clinical Challenges and Prospects

Course Slides in PDF (Single or 3/page)

Special Session for High School Students

Introduction to Nanomedicine

A special session to introduce nanomedicine to high-school students was organized during the International Conference on Nanotheranostics (ICoN 2013) poster session. About 50 students and teachers had a chance to attend a lecture, watch a short movie and attend the poster session.

• Introduction to Nanomedicine for High School Students (in Greek) (PDF).

Advanced Summer School 2013 - Managing Drug Resistance with Nanomedicine

The Advanced Summer School was designed to train young scientists in research activities in this emerging scientific area of major clinical significance. Its goal was to overcome the fragmented and disseminated expertise of academic and industrial groups involved in this new research domain and to foster technology transfer. The vibrant inter-sectoral mobility program of NANORESISTANCE played a structuring role by allowing researchers to acquire key skills which are equally relevant to the public and private sectors.

You can access the presentations delivered at the summer scholl below :

Session 1 – Introduction

• Cancer Biology and Signal Transduction (Andreani Odysseos, Conference Chair, EPOS-Iasis R&D Ltd, EFB) (PDF)
• Light-Tissue Interaction (Costas Pitris, University of Cyprus ) (PDF)

Session 2 – Tissue Mechanics and Molecular Imaging I

• Introduction to tissue mechanics (Triantafyllos Stylianopoullos, University of Cyprus ) (PDF)
• Optical molecular imaging and endoscopic approaches (Costas Pitris, University of Cyprus) (PDF)

Session 3 – Tissue Mechanics and Molecular Imaging II

• Whole body imaging and in vivo cytology (Costas Pitsillides, Cyprus University of Technology) (PDF)

Session 4 – Nanomaterials I

• Metal based nanoparticles for biomedical applications: an introduction (Jean-Michel Siaugue, Université Pierre et Marie Curie, France) (PDF)
• Carbon nanomaterials: from toxicology to pharmacology (Cyrill Bussy, University College London / University of Manchester) (PDF)

Session 5 – Nanomaterials II

• Metal based nanoparticles for biomedical applications: an overview (Jean-Michel Siaugue, Université Pierre et Marie Curie, France) (PDF)
• Carbon nanomaterials as nanomedicines: state of the art and challenges (Cyrill Bussy, University College London / University of Manchester) (PDF)

Session 6-8 – Roadmap to Commercialization

• Evaluation Part 1 (Louise Rosenmayr-Templeton, Tower Pharma Consulting, Austria) (PDF)
• Evaluation Part 2 (Louise Rosenmayr-Templeton, Tower Pharma Consulting, Austria) (PDF)
• Commercialization Part 1&2 (Louise Rosenmayr-Templeton, Tower Pharma Consulting, Austria) (PDF)
• Commercialization Part 3 (Louise Rosenmayr-Templeton, Tower Pharma Consulting, Austria) (PDF)
• Pharmaceutical Development Process (Louise Rosenmayr-Templeton, Tower Pharma Consulting, Austria) (PDF)

Session 9 – Synthesis and Screening I

• Strategies and Tactics in Organic Synthesis (Alexandros Strongylos, Proactina SA) (Available to NanoResistance partners only)
• How can Surface Plasmon Resonance help nanomedicine (Bogos (Pavlos) Agianian, Democritus University of Thrace) (PDF)

Session 10 –Synthesis and Screening II

• Nanoparticle Alboumin Bound (NAB) technologies: Abraxane the new generation of taxane cancer therapy (Alexandros Strongylos, Proactina SA) (Available to NanoResistance partners only)
• Receptor-mediated nanodelivery (Bogos (Pavlos) Agianian, Democritus University of Thrace) (PDF)